Released Nov 14, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0000950170-22-024971
Q3 2022 · 10-Q
Revenue$1.08M$1.08M +52.8% vs Q3 2021+20.8% vs Q2 2022
Net Income-$11.70M-$11.70M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.33-$0.33 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$11,834,000N/M
Operating Cash Flowderived-$957,000N/M
Margins · derived
Operating margin-1093.7%+2087.6 pt vs Q3 2021
Net margin-1081.3%+2096.6 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $1.08M | $708.00K | $38.00K | $172.00K |
| Net Income | -$11.70M | -$22.50M | -$18.90M | -$17.70M |
| EPS Diluted | -$0.33 | -$0.70 | -$0.86 | -$0.95 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR